Management of osteoporosis.
Accelerated bone loss and diminished new bone formation in primary involutional osteoporosis far outstrip the rates seen in "normal aging." Their serious consequences can be mitigated with pharmacologic agents and adjunctive regimens.
D000368:Aged; D000728:Androgens / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005006:Ethnicity; D005260:Female; D006801:Humans; D008297:Male; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D012737:Sex Factors; D012969:Sodium Fluoride / Q000627:therapeutic use
D000728:Androgens; D004967:Estrogens; D012969:Sodium Fluoride; D002116:Calcitonin